Active	Status	Sponsor type	Region	Phase	Filter
15 Active 7 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Li, Haiyan
NCT03894163: A Phase I Study of Etrasimod in Healthy Chinese Audlt Subjects.	Recruiting	1	36	RoW	Etrasimod, Etrasimod Placebo	Everstar Therapeutics Limited	Healthy Volunteers	06/19	10/19
NCT04613999: A Study of Ralinepag in Healthy Chinese Adult Subjects	Completed	1	15	RoW	Ralinepag	Everstar Medicines (Shanghai) Limited	Healthy Volunteer, Pharmacokinetic Study	11/20	11/20
NCT05757596: Study of VSA001 Injection in Chinese Healthy Adult Volunteers	Completed	1	24	RoW	VSA001 injection, Placebo	Visirna Therapeutics HK Limited, Arrowhead Pharmaceuticals	Healthy Adult Volunteers	09/23	12/23
NCT06344533: Study of JMKX003142 Injection in Chinese Healthy Subjects	Not yet recruiting	1	78	RoW	JMKX003142 Injection, Placebo	Jemincare, Zhejiang Hangyu Pharmaceutical Co., Ltd	Healthy Adult	01/25	05/25
NCT06501586: Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects	Recruiting	1	48	RoW	SGB-3908, SGB-3908-Matching placebo	Suzhou Sanegene Bio Inc., Innovent Biologics (Suzhou) Co. Ltd.	Hypertension,Essential	08/25	01/26
NCT06563713: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STSP-0902 in Healthy Subjects	Active, not recruiting	1	40	RoW	STSP-0902 injection, Placebo	Staidson (Beijing) Biopharmaceuticals Co., Ltd	Oligozoospermia, Asthenozoospermia	04/25	04/25
NCT06543459: To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects	Not yet recruiting	1	16	RoW	MY008211A tablets, Placebo	Wuhan Createrna Science and Technology Co., Ltd	Paroxysmal Nocturnal Hemoglobinuria	09/24	12/24
NCT06090799: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects	Completed	1	6	RoW	SHR-3032, SHR-3032 Placebo	Guangdong Hengrui Pharmaceutical Co., Ltd	Prevention of Graft Rejection After Organ Transplantation	03/24	04/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Li, Haiyan
NCT03894163: A Phase I Study of Etrasimod in Healthy Chinese Audlt Subjects.	Recruiting	1	36	RoW	Etrasimod, Etrasimod Placebo	Everstar Therapeutics Limited	Healthy Volunteers	06/19	10/19
NCT04613999: A Study of Ralinepag in Healthy Chinese Adult Subjects	Completed	1	15	RoW	Ralinepag	Everstar Medicines (Shanghai) Limited	Healthy Volunteer, Pharmacokinetic Study	11/20	11/20
NCT05757596: Study of VSA001 Injection in Chinese Healthy Adult Volunteers	Completed	1	24	RoW	VSA001 injection, Placebo	Visirna Therapeutics HK Limited, Arrowhead Pharmaceuticals	Healthy Adult Volunteers	09/23	12/23
NCT06344533: Study of JMKX003142 Injection in Chinese Healthy Subjects	Not yet recruiting	1	78	RoW	JMKX003142 Injection, Placebo	Jemincare, Zhejiang Hangyu Pharmaceutical Co., Ltd	Healthy Adult	01/25	05/25
NCT06501586: Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects	Recruiting	1	48	RoW	SGB-3908, SGB-3908-Matching placebo	Suzhou Sanegene Bio Inc., Innovent Biologics (Suzhou) Co. Ltd.	Hypertension,Essential	08/25	01/26
NCT06563713: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STSP-0902 in Healthy Subjects	Active, not recruiting	1	40	RoW	STSP-0902 injection, Placebo	Staidson (Beijing) Biopharmaceuticals Co., Ltd	Oligozoospermia, Asthenozoospermia	04/25	04/25
NCT06543459: To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects	Not yet recruiting	1	16	RoW	MY008211A tablets, Placebo	Wuhan Createrna Science and Technology Co., Ltd	Paroxysmal Nocturnal Hemoglobinuria	09/24	12/24
NCT06090799: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects	Completed	1	6	RoW	SHR-3032, SHR-3032 Placebo	Guangdong Hengrui Pharmaceutical Co., Ltd	Prevention of Graft Rejection After Organ Transplantation	03/24	04/24